SHANGHAI – Inventisbio Inc., of Shanghai, has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV). Founded in 2015, Inventisbio has a pipeline of four small-molecule preclinical drug candidates for cancer and gout.
SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC).
ZHUHAI, China – When attending the ChinaBio Partnering Forum, there are a few options for how to spend the time: go to one-on-one meetings, take in a few panels, or dip in and out of a marathon of 15-minute company presentations.
ZHUHAI, China – When attending the ChinaBio Partnering Forum, there are a few options for how to spend the time: go to one-on-one meetings, take in a few panels, or dip in and out of a marathon of 15-minute company presentations. The first day is reserved for biotech presentations, while day two is dominated by multinational biopharmas.
ZHUHAI, China – Attendees at what has become one of Asia's most important annual partnering meetings heard multinational company and local biopharma execs talk optimistically about positive changes the CFDA proposed just weeks ago, which promise to open the doors to China's market for novel drugs.
ZHUHAI, China – Attendees at what has become one of Asia's most important annual partnering meetings heard multinational company and local biopharma execs talk optimistically about positive changes the CFDA proposed just weeks ago, which promise to open the doors to China's market for novel drugs.
SHANGHAI – The hot topic at the 9th DIA China annual meeting was China's proposed entry into the ICH, a global body that facilitates the harmonizing of drug regulations across countries. Acceptance into the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) would be a major milestone for China's regulatory reform efforts and give the drug industry a leg up on the global stage.
SHANGHAI – The hot topic at the 9th DIA China annual meeting was China's proposed entry into the ICH, a global body that facilitates the harmonizing of drug regulations across countries.
SHANGHAI – Innovative Cellular Therapeutics Co. Ltd. (ICT), of Shanghai, a leader among China's pack of emerging CAR T oncology companies, has struck a partnership deal with Vericel Corp., the first biotech to receive FDA approval for a tissue-engineered autologous cell scaffold.
SHANGHAI – Innovative Cellular Therapeutics Co. Ltd. (ICT), of Shanghai, a leader among China's pack of emerging CAR T oncology companies, has struck a partnership deal with Vericel Corp., the first biotech to receive FDA approval for a tissue-engineered autologous cell scaffold.
